ZyVersa Therapeutics, Inc. (ZVSA)
↓ Download CSV| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Income | -$25.49M | -$9.14M | -$107.75M | — | — |
| Net Income | -$24.95M | -$9.41M | -$98.30M | — | — |
| EPS (Diluted) | $-4.18 | $-8.48 | $-1089.70 | — | — |
| Total Assets | $347.9K | $20.60M | $22.11M | $118.51M | $77.14M |
| Total Liabilities | $12.73M | $12.08M | $11.04M | $18.51M | $3.65M |
| Shareholders' Equity | -$12.39M | $8.52M | $11.07M | $99.66M | -$2.26M |
| Cash & Equivalents | — | — | — | — | $928.4K |
| Operating Cash Flow | -$5.11M | -$7.52M | -$8.72M | — | — |
| Shares Outstanding | 8.10M | 2.51M | 402.2K | 257.6K | — |